Research

Hormonal

Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.

Beyond weight loss, semaglutide helps improve blood sugar control (HbA1c), blood pressure, and lipid profiles in overweight/obese individuals, offering broader cardiovascular protection.

StrongSupportsHIGH confidence
Semaglutide also reduced BMI and WC, and benefited glycaemic, blood pressure and triglyceride regulation.
Mengjun Wang et al. · Research Square · 2022

Why this rating

Meta-analysis of 9 RCTs.

Source

Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis

Mengjun Wang et al. · Research Square · 2022

DOI 10.21203/rs.3.rs-2346356/v1

Meta-analysis · 9 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →